Godavari Drugs

Market Cap: Micro Cap
Industry: Pharmaceuticals & Biotechnology
ISIN: INE362C01012
NSEID:
BSEID: 530317
View on BSE

INR

77.27

1.67 (2.21%)

BSENSE

Mar 05

BSE+NSE Vol: 4.11 k

{
  "main_header": {
    "sid": 765253,
    "name": "Godavari Drugs",
    "stock_name": "Godavari Drugs",
    "full_name": "Godavari Drugs Ltd",
    "name_url": "stocks-analysis/godavari-drugs",
    "exchange": 0,
    "exchangecode": "",
    "primexch": 0,
    "country_id": 34,
    "currency": "INR",
    "cmp": "77.27",
    "chg": 1.67,
    "chgp": "2.21%",
    "dir": 1,
    "prev_price": "75.60",
    "mcapval": "57.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 530317,
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE362C01012",
    "curr_date": "Mar 05",
    "curr_time": "",
    "bse_nse_vol": "4.11 k",
    "exc_status": "Active",
    "traded_date": "Mar 05, 2026",
    "traded_date_str": "2026 03 05",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/godavari-drugs-765253-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Godavari Drugs Ltd Upgraded to Sell on Technical Improvement Despite Weak Fundamentals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/godavari-drugs-ltd-upgraded-to-sell-on-technical-improvement-despite-weak-fundamentals-3872786",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/GodavariDrugsLt_mojoScore_3872786.png",
        "date": "2026-03-05 08:08:10",
        "description": "Godavari Drugs Ltd has seen its investment rating downgraded from Strong Sell to Sell as of 4 March 2026, reflecting a complex interplay of technical indicators, valuation metrics, financial trends, and overall quality assessments. Despite some mild improvements in technical signals, the company’s weak long-term fundamentals and flat recent financial performance have weighed heavily on investor sentiment."
      },
      {
        "title": "Godavari Drugs Ltd Forms Golden Cross, Indicating Potential Bullish Breakout",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/godavari-drugs-ltd-forms-golden-cross-indicating-potential-bullish-breakout-3870618",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/GodavariDrugsLt_goldencross_3870618.png",
        "date": "2026-03-04 18:00:11",
        "description": "Godavari Drugs Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has recently formed a Golden Cross, a significant technical indicator where the 50-day moving average (DMA) has crossed above the 200-day moving average. This development often signals a potential bullish breakout and a shift in long-term momentum, attracting investor attention despite the company’s current strong sell rating and subdued financial performance."
      },
      {
        "title": "Godavari Drugs Ltd Downgraded to Strong Sell Amid Weak Financials and Bearish Technicals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/godavari-drugs-ltd-downgraded-to-strong-sell-amid-weak-financials-and-bearish-technicals-3852277",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/GodavariDrugsLt_mojoScore_3852277.png",
        "date": "2026-02-24 08:10:50",
        "description": "Godavari Drugs Ltd, a player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Sell to Strong Sell as of 23 February 2026. This shift reflects deteriorating technical indicators, flat financial performance, and a cautious outlook on valuation and quality metrics, signalling increased risk for investors amid challenging market conditions."
      },
      {
        "title": "Godavari Drugs Ltd Falls 3.99%: Valuation Gains Amid Flat Financials Shape the Week",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/godavari-drugs-ltd-falls-399-valuation-gains-amid-flat-financials-shape-the-week-3849734",
        "imagepath": "",
        "date": "2026-02-21 15:02:58",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <div class=\"highlight-box\">\n                    <h3>Key Events This Week</h3>\n                    <p><strong>16 Feb:</strong> Stock opens at Rs.88.19, gaining 1.07% amid positive market sentiment</p>\n                    <p><strong>18 Feb:</strong> Mojo Grade upgraded to 'Sell' on valuation improvement despite flat financials</p>\n                    <p><strong>19 Feb:</strong> Stock declines 3.48% following rating upgrade and valuation shift</p>\n                    <p><strong>20 Feb:</strong> Week closes at Rs.83.78, down 1.87% on the day and 3.99% for the week</p>\n                </div>\n\n                <div class=\"stats-row\">\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.87.26</div></div>\n                    <div class=\"stat..."
      },
      {
        "title": "Godavari Drugs Ltd Upgraded to Sell on Valuation Improvement Despite Flat Financials",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/godavari-drugs-ltd-upgraded-to-sell-on-valuation-improvement-despite-flat-financials-3846406",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/GodavariDrugsLt_mojoScore_3846406.png",
        "date": "2026-02-19 08:07:23",
        "description": "Godavari Drugs Ltd has seen its investment rating upgraded from Strong Sell to Sell, driven primarily by a marked improvement in valuation metrics despite ongoing challenges in financial performance and market returns. The pharmaceutical company’s recent assessment highlights a very attractive valuation grade, while quality, financial trends, and technical indicators remain subdued, reflecting a cautious outlook for investors."
      },
      {
        "title": "Godavari Drugs Ltd Valuation Shifts to Very Attractive Amid Market Volatility",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/godavari-drugs-ltd-valuation-shifts-to-very-attractive-amid-market-volatility-3846255",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/GodavariDrugsLt_valuationdot_3846255.png",
        "date": "2026-02-19 08:01:24",
        "description": "Godavari Drugs Ltd has witnessed a notable shift in its valuation parameters, moving from an attractive to a very attractive rating, despite recent share price declines and sector headwinds. This recalibration in price-to-earnings and price-to-book value metrics positions the pharmaceutical company as a compelling consideration for investors seeking value within the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "Are Godavari Drugs Ltd latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-godavari-drugs-ltd-latest-results-good-or-bad-3835642",
        "imagepath": "",
        "date": "2026-02-12 19:38:46",
        "description": "Godavari Drugs Ltd's latest financial results reflect a complex operational landscape characterized by both challenges and modest improvements. In the second quarter of FY26, the company reported net sales of ₹26.65 crores, which indicates a sequential growth of 11.93% from the previous quarter, but only a slight year-on-year increase of 2.15%. This modest growth is indicative of the ongoing difficulties faced by active pharmaceutical ingredient (API) manufacturers, particularly in light of pricing pressures and fluctuating demand.\n\nHowever, the profitability metrics present a more concerning picture. The net profit for Q2 FY26 was ₹1.00 crore, which represents a decline of 8.26% year-on-year. The operating margin also contracted significantly to 7.47%, down from 11.12% in the same quarter last year, highlighting the impact of rising input costs and competitive pressures on operational efficiency. The profi..."
      },
      {
        "title": "Godavari Drugs Q3 FY26: Modest Recovery Amid Persistent Margin Pressures",
        "link": "https://www.marketsmojo.com/news/result-analysis/godavari-drugs-q3-fy26-modest-recovery-amid-persistent-margin-pressures-3833869",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/GodavariDrugs_quaterlyResult_3833869.png",
        "date": "2026-02-11 20:05:59",
        "description": "Godavari Drugs Ltd., a micro-cap active pharmaceutical ingredients (API) manufacturer, reported a marginal sequential improvement in Q2 FY26 (July-September 2025), with net profit of ₹1.00 crores representing a decline of 3.85% quarter-on-quarter but an 8.26% decline year-on-year. The company, with a market capitalisation of ₹67.00 crores, continues to grapple with revenue volatility and compressed profitability margins, reflecting ongoing challenges in the API manufacturing landscape."
      },
      {
        "title": "Are Godavari Drugs Ltd latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-godavari-drugs-ltd-latest-results-good-or-bad-3833392",
        "imagepath": "",
        "date": "2026-02-11 19:30:17",
        "description": "The latest financial results for Godavari Drugs Ltd for the quarter ending September 2025 reflect a complex operational landscape. The company reported net sales of ₹26.65 crores, which represents a sequential growth of 11.93% compared to the previous quarter's ₹23.81 crores. However, year-on-year growth is modest at just 2.15%, indicating that while there is some recovery in sales, it is not keeping pace with broader market expectations.\n\nIn terms of profitability, net profit for the quarter was ₹1.00 crore, reflecting a decline of 3.85% from the previous quarter and an 8.26% decrease year-on-year. This decline in profit is concerning, especially as it coincides with a significant drop in operating margins, which fell to 7.47%, the lowest level recorded in the past seven quarters. This margin compression is indicative of ongoing challenges, including rising input costs and pricing pressures in the active p..."
      }
    ],
    "total": 164,
    "sid": "765253",
    "stock_news_url": "https://www.marketsmojo.com/news/godavari-drugs-765253"
  },
  "announcements": [
    {
      "caption": "Shareholder Meeting / Postal Ballot-Outcome of EGM",
      "datetime": "12-Feb-2026",
      "details": "Outcome of the EGM held on 12.02.2026",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
      "datetime": "12-Feb-2026",
      "details": "Newspaper Publication of Financial Results for the quarter and nine months ended 31st December 2025",
      "source": "BSE"
    },
    {
      "caption": "Shareholder Meeting / Postal Ballot-Scrutinizers Report",
      "datetime": "12-Feb-2026",
      "details": "Disclosure under Regulation 44 (3) of SEBI (LODR) Regulations 2015",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Godavari Drugs Ltd Upgraded to Sell on Technical Improvement Despite Weak Fundamentals

2026-03-05 08:08:10

Godavari Drugs Ltd has seen its investment rating downgraded from Strong Sell to Sell as of 4 March 2026, reflecting a complex interplay of technical indicators, valuation metrics, financial trends, and overall quality assessments. Despite some mild improvements in technical signals, the company’s weak long-term fundamentals and flat recent financial performance have weighed heavily on investor sentiment.

Read full news article

Godavari Drugs Ltd Forms Golden Cross, Indicating Potential Bullish Breakout

2026-03-04 18:00:11

Godavari Drugs Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has recently formed a Golden Cross, a significant technical indicator where the 50-day moving average (DMA) has crossed above the 200-day moving average. This development often signals a potential bullish breakout and a shift in long-term momentum, attracting investor attention despite the company’s current strong sell rating and subdued financial performance.

Read full news article

Godavari Drugs Ltd Downgraded to Strong Sell Amid Weak Financials and Bearish Technicals

2026-02-24 08:10:50

Godavari Drugs Ltd, a player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Sell to Strong Sell as of 23 February 2026. This shift reflects deteriorating technical indicators, flat financial performance, and a cautious outlook on valuation and quality metrics, signalling increased risk for investors amid challenging market conditions.

Read full news article

Godavari Drugs Ltd Falls 3.99%: Valuation Gains Amid Flat Financials Shape the Week

2026-02-21 15:02:58

Key Events This Week

16 Feb: Stock opens at Rs.88.19, gaining 1.07% amid positive market sentiment

18 Feb: Mojo Grade upgraded to 'Sell' on valuation improvement despite flat financials

19 Feb: Stock declines 3.48% following rating upgrade and valuation shift

20 Feb: Week closes at Rs.83.78, down 1.87% on the day and 3.99% for the week

Week Open

Rs.87.26

Read full news article

Godavari Drugs Ltd Upgraded to Sell on Valuation Improvement Despite Flat Financials

2026-02-19 08:07:23

Godavari Drugs Ltd has seen its investment rating upgraded from Strong Sell to Sell, driven primarily by a marked improvement in valuation metrics despite ongoing challenges in financial performance and market returns. The pharmaceutical company’s recent assessment highlights a very attractive valuation grade, while quality, financial trends, and technical indicators remain subdued, reflecting a cautious outlook for investors.

Read full news article

Godavari Drugs Ltd Valuation Shifts to Very Attractive Amid Market Volatility

2026-02-19 08:01:24

Godavari Drugs Ltd has witnessed a notable shift in its valuation parameters, moving from an attractive to a very attractive rating, despite recent share price declines and sector headwinds. This recalibration in price-to-earnings and price-to-book value metrics positions the pharmaceutical company as a compelling consideration for investors seeking value within the Pharmaceuticals & Biotechnology sector.

Read full news article

Are Godavari Drugs Ltd latest results good or bad?

2026-02-12 19:38:46

Godavari Drugs Ltd's latest financial results reflect a complex operational landscape characterized by both challenges and modest improvements. In the second quarter of FY26, the company reported net sales of ₹26.65 crores, which indicates a sequential growth of 11.93% from the previous quarter, but only a slight year-on-year increase of 2.15%. This modest growth is indicative of the ongoing difficulties faced by active pharmaceutical ingredient (API) manufacturers, particularly in light of pricing pressures and fluctuating demand. However, the profitability metrics present a more concerning picture. The net profit for Q2 FY26 was ₹1.00 crore, which represents a decline of 8.26% year-on-year. The operating margin also contracted significantly to 7.47%, down from 11.12% in the same quarter last year, highlighting the impact of rising input costs and competitive pressures on operational efficiency. The profi...

Read full news article

Godavari Drugs Q3 FY26: Modest Recovery Amid Persistent Margin Pressures

2026-02-11 20:05:59

Godavari Drugs Ltd., a micro-cap active pharmaceutical ingredients (API) manufacturer, reported a marginal sequential improvement in Q2 FY26 (July-September 2025), with net profit of ₹1.00 crores representing a decline of 3.85% quarter-on-quarter but an 8.26% decline year-on-year. The company, with a market capitalisation of ₹67.00 crores, continues to grapple with revenue volatility and compressed profitability margins, reflecting ongoing challenges in the API manufacturing landscape.

Read full news article

Are Godavari Drugs Ltd latest results good or bad?

2026-02-11 19:30:17

The latest financial results for Godavari Drugs Ltd for the quarter ending September 2025 reflect a complex operational landscape. The company reported net sales of ₹26.65 crores, which represents a sequential growth of 11.93% compared to the previous quarter's ₹23.81 crores. However, year-on-year growth is modest at just 2.15%, indicating that while there is some recovery in sales, it is not keeping pace with broader market expectations. In terms of profitability, net profit for the quarter was ₹1.00 crore, reflecting a decline of 3.85% from the previous quarter and an 8.26% decrease year-on-year. This decline in profit is concerning, especially as it coincides with a significant drop in operating margins, which fell to 7.47%, the lowest level recorded in the past seven quarters. This margin compression is indicative of ongoing challenges, including rising input costs and pricing pressures in the active p...

Read full news article

View All News